XML 29 R7.htm IDEA: XBRL DOCUMENT v3.24.2
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Total Edwards Lifesciences Corporation Stockholders' Equity
Common Stock
Treasury Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2022     646.3          
Beginning balance at Dec. 31, 2022 $ 5,806.7 $ 5,806.7 $ 646.3 $ (4,144.0) $ 1,969.3 $ 7,590.0 $ (254.9) $ 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2022       38.0        
Increase (Decrease) in Stockholders' Equity                
Net income 340.5 340.5       340.5    
Other comprehensive gain (loss), net of tax (0.5) (0.5)         (0.5)  
Common stock issued under stock plans (in shares)     0.8          
Common stock issued under stock plans 41.9 41.9 $ 0.8   41.1      
Stock-based compensation expense 38.9 38.9     38.9      
Purchases of treasury stock (in shares)       3.1        
Purchases of treasury stock (249.5) (249.5)   $ (249.5)        
Changes to noncontrolling interest 84.0             84.0
Common stock, ending balance (in shares) at Mar. 31, 2023     647.1          
Ending balance at Mar. 31, 2023 6,062.0 5,978.0 $ 647.1 $ (4,393.5) 2,049.3 7,930.5 (255.4) 84.0
Treasury stock, ending balance (in shares) at Mar. 31, 2023       41.1        
Common stock, beginning balance (in shares) at Dec. 31, 2022     646.3          
Beginning balance at Dec. 31, 2022 5,806.7 5,806.7 $ 646.3 $ (4,144.0) 1,969.3 7,590.0 (254.9) 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2022       38.0        
Increase (Decrease) in Stockholders' Equity                
Net income 646.0              
Common stock, ending balance (in shares) at Jun. 30, 2023     649.1          
Ending balance at Jun. 30, 2023 6,446.5 6,375.7 $ 649.1 $ (4,401.0) 2,145.5 8,237.6 (255.5) 70.8
Treasury stock, ending balance (in shares) at Jun. 30, 2023       41.2        
Common stock, beginning balance (in shares) at Mar. 31, 2023     647.1          
Beginning balance at Mar. 31, 2023 6,062.0 5,978.0 $ 647.1 $ (4,393.5) 2,049.3 7,930.5 (255.4) 84.0
Treasury stock, beginning balance (in shares) at Mar. 31, 2023       41.1        
Increase (Decrease) in Stockholders' Equity                
Net income 305.5 307.1       307.1   (1.6)
Other comprehensive gain (loss), net of tax (0.1) (0.1)         (0.1)  
Common stock issued under stock plans (in shares)     2.0          
Common stock issued under stock plans 60.8 60.8 $ 2.0   58.8      
Stock-based compensation expense 37.4 37.4     37.4      
Purchases of treasury stock (in shares)       0.1        
Purchases of treasury stock (7.5) (7.5)   $ (7.5)        
Changes to noncontrolling interest (11.6)             (11.6)
Common stock, ending balance (in shares) at Jun. 30, 2023     649.1          
Ending balance at Jun. 30, 2023 $ 6,446.5 6,375.7 $ 649.1 $ (4,401.0) 2,145.5 8,237.6 (255.5) 70.8
Treasury stock, ending balance (in shares) at Jun. 30, 2023       41.2        
Common stock, beginning balance (in shares) at Dec. 31, 2023 601.1   650.5          
Beginning balance at Dec. 31, 2023 $ 6,719.4 6,650.0 $ 650.5 $ (5,024.5) 2,274.4 8,992.4 (242.8) 69.4
Treasury stock, beginning balance (in shares) at Dec. 31, 2023 49.4     49.4        
Increase (Decrease) in Stockholders' Equity                
Net income $ 351.0 351.9       351.9   (0.9)
Other comprehensive gain (loss), net of tax 9.5 9.5         9.5  
Common stock issued under stock plans (in shares)     1.3          
Common stock issued under stock plans 62.1 62.1 $ 1.3   60.8      
Stock-based compensation expense 44.6 44.6     44.6      
Purchases of treasury stock (0.2) (0.2)   $ (0.2)        
Common stock, ending balance (in shares) at Mar. 31, 2024     651.8          
Ending balance at Mar. 31, 2024 $ 7,186.4 7,117.9 $ 651.8 $ (5,024.7) 2,379.8 9,344.3 (233.3) 68.5
Treasury stock, ending balance (in shares) at Mar. 31, 2024       49.4        
Common stock, beginning balance (in shares) at Dec. 31, 2023 601.1   650.5          
Beginning balance at Dec. 31, 2023 $ 6,719.4 6,650.0 $ 650.5 $ (5,024.5) 2,274.4 8,992.4 (242.8) 69.4
Treasury stock, beginning balance (in shares) at Dec. 31, 2023 49.4     49.4        
Increase (Decrease) in Stockholders' Equity                
Net income $ 716.0              
Common stock, ending balance (in shares) at Jun. 30, 2024 602.3   653.5          
Ending balance at Jun. 30, 2024 $ 7,504.6 7,437.4 $ 653.5 $ (5,182.8) 2,476.3 9,710.6 (220.2) 67.2
Treasury stock, ending balance (in shares) at Jun. 30, 2024 51.2     51.2        
Common stock, beginning balance (in shares) at Mar. 31, 2024     651.8          
Beginning balance at Mar. 31, 2024 $ 7,186.4 7,117.9 $ 651.8 $ (5,024.7) 2,379.8 9,344.3 (233.3) 68.5
Treasury stock, beginning balance (in shares) at Mar. 31, 2024       49.4        
Increase (Decrease) in Stockholders' Equity                
Net income 365.0 366.3       366.3   (1.3)
Other comprehensive gain (loss), net of tax 13.1 13.1         13.1  
Common stock issued under stock plans (in shares)     1.7          
Common stock issued under stock plans 54.3 54.3 $ 1.7   52.6      
Stock-based compensation expense 43.9 43.9     43.9      
Purchases of treasury stock (in shares)       1.8        
Purchases of treasury stock $ (158.1) (158.1)   $ (158.1)        
Common stock, ending balance (in shares) at Jun. 30, 2024 602.3   653.5          
Ending balance at Jun. 30, 2024 $ 7,504.6 $ 7,437.4 $ 653.5 $ (5,182.8) $ 2,476.3 $ 9,710.6 $ (220.2) $ 67.2
Treasury stock, ending balance (in shares) at Jun. 30, 2024 51.2     51.2